Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Orexo Ab (ORXOY)

Orexo Ab (ORXOY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 13.01
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.8890 +24.86%
on 10/28/24
1.5500 -28.39%
on 10/11/24
-0.4000 (-26.49%)
since 08/30/24
3-Month
0.8890 +24.86%
on 10/28/24
1.8600 -40.32%
on 08/28/24
-0.4900 (-30.63%)
since 07/24/24

Most Recent Stories

More News
Orexo announces data from the MODIA® study evaluating impact on use of illicit opioids

The six-month randomized controlled trial (RCT) enrolled 437 participants at 36 sites across the US The study demonstrated no statistically significant...

ORXOY : 1.1100 (+24.86%)
Orexo submits New Drug Application to FDA for OX124, a high-dose rescue medication for opioid overdose

/PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), today announces the submission of the New Drug Application (NDA) to the US Food and Drug...

ORXOY : 1.1100 (+24.86%)
Orexo to participate in Pareto Securities´ 14th Annual Healthcare Conference 2023

/PRNewswire/ -- Orexo AB (Publ.), (STO:ORX) (OTCQX:ORXOY), today announces the company will participate in Pareto Securities' 14th Annual Healthcare...

ORXOY : 1.1100 (+24.86%)
Orexo secures patent protection in the US for OX640, a nasal epinephrine powder product

/PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY) today announces that the United States Patent and Trademark Office (USPTO) has granted the first US...

ORXOY : 1.1100 (+24.86%)
Orexo's patent win for ZUBSOLV® appealed

/PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), today announces that Sun Pharmaceutical Industries Limited, Sun Pharma Global FZE, Sun Pharma...

ORXOY : 1.1100 (+24.86%)
Orexo wins patent litigation for ZUBSOLV® in the US

/PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), today announces that the US District Court for the District of New Jersey ruled in favor of Orexo...

ORXOY : 1.1100 (+24.86%)
Orexo shares new timeline for the high-dose rescue medication for opioid overdose, OX124

/PRNewswire/ -- Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today announces the expected US launch of OX124, a high-dose rescue medication for opioid overdose,...

ORXOY : 1.1100 (+24.86%)
Orexo postpones publication of the Annual Report

/PRNewswire/ -- Orexo AB (publ), (STO:ORX) (OTCQX:ORXOY), has resolved to postpone the publication of the Annual Report for 2022 to March 28, 2023. The...

ORXOY : 1.1100 (+24.86%)
Orexo submits New Drug Application to FDA for OX124, a high-dose rescue medication for opioid overdose

/PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), today announces the submission of a New Drug Application (NDA) to the US Food and Drug...

ORXOY : 1.1100 (+24.86%)
Orexo initiates exploratory feasibility studies of amorphOX® with two leading biopharmaceutical and vaccine companies

/PRNewswire/ -- Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today announces the company has initiated two exploratory feasibility studies, applying the...

ORXOY : 1.1100 (+24.86%)

Business Summary

Orexo AB is a pharmaceutical company. It develops and improves products and treatments based on proprietary drug delivery technology. Its main products are Abstral, Edluar, Diabact UBT, and Heliprobe System. Abstral is a drug that provides fast and effective treatment of breakthrough pain in cancer patients....

See More

Key Turning Points

3rd Resistance Point 1.1100
2nd Resistance Point 1.1100
1st Resistance Point 1.1100
Last Price 1.1100
1st Support Level 1.1100
2nd Support Level 1.1100
3rd Support Level 1.1100

See More

52-Week High 2.3500
Fibonacci 61.8% 1.7919
Fibonacci 50% 1.6195
Fibonacci 38.2% 1.4471
Last Price 1.1100
52-Week Low 0.8890

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar